Antares Vision (AV) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
6 Jun, 2025Executive summary
FY 2024 revenues reached €208M, up 2% year-over-year, with 4Q 2024 sales surging 20% and order intake rising 16%, led by strong growth in Americas (+26%) and Europe (+18%).
Orders for FY 2024 increased 9% year-over-year, with 4Q orders up 16%, indicating robust demand acceleration.
Adjusted EBITDA margin for FY 2024 exceeded the guidance range of 11.5–14%.
Net Financial Position improved to €84M at year-end, down from €104M at end-2023, mainly due to operating cash flow and working capital optimization.
NFP/EBITDA ratio improved to below 4.1–3.3x, from 7.8x at end-2023.
Financial highlights
FY 2024 revenues: €208M (+2% year-over-year); 4Q 2024 revenues: €80M (+20% year-over-year).
Recurring revenues represented 38% of FY 2024 turnover, up from 37% in FY 2023.
4Q 2024 recurring revenues grew 6% year-over-year, accounting for 27% of total revenues.
Europe and Italy drove order growth (+27% and +7% respectively), while Americas saw a 7% decline for the year but rebounded in 4Q (+49%).
By geography, FY 2024 revenues: Italy +16%, Europe +8%, Americas -9%, Asia & Oceania +8%, Africa & Middle East -9%.
Outlook and guidance
Adjusted EBITDA margin for FY 2024 is expected to exceed the guidance range of 11.5–14%.
NFP/EBITDA at year-end 2024 will be lower than the guidance of 4.1–3.3x and significantly improved from 7.8x at year-end 2023.
Robust 4Q 2024 order acceleration is expected to drive a positive start to 2025.
Continued focus on cost containment, production efficiency, and working capital management to drive further margin and cash flow improvements.
FY 2024 results will be published on March 24, 2025; 2025–2027 strategic plan to be presented in Q2 2025.
Latest events from Antares Vision
- FY 2025 revenues fell 2% to €204M, with SCT and recurring revenue growth offsetting Life Science weakness.AV
Q4 202513 Feb 2026 - 9M 2025 revenues up 5% to €134M; FY outlook flat with lower EBITDA margin expected.AV
Q3 202514 Nov 2025 - Orders up 14%, revenues rose 3.3%, EBITDA doubled, and net loss narrowed in 1H 2025.AV
Q2 202512 Sep 2025 - Margins and cash flow improved as orders rose and full-year guidance was confirmed.AV
Q3 202413 Jun 2025 - Adjusted EBITDA rebounded to €3.4M as recurring business and margins improved.AV
Q2 202413 Jun 2025 - 2024-2026 plan aims for strong revenue and EBITDA growth, driven by innovation and efficiency.AV
Strategy Update13 Jun 2025 - Q1 2025 orders up 25% year-over-year, with recurring revenues at 49% of total.AV
Q1 20256 Jun 2025 - Profitability and cash flow surged, with recurring revenues and leverage improving.AV
H2 20246 Jun 2025